BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

950 related articles for article (PubMed ID: 18482181)

  • 1. Platelet products prepared by different methods of sedimentation undergo platelet activation differently during storage.
    Skripchenko A; Kurtz J; Moroff G; Wagner SJ
    Transfusion; 2008 Jul; 48(7):1469-77. PubMed ID: 18482181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of simulated shipping conditions (24- or 30-hr interruption of agitation) on the in vitro properties of apheresis platelets during 7-day storage.
    Wagner SJ; Vassallo R; Skripchenko A; Einarson M; Seetharaman S; Moroff G
    Transfusion; 2008 Jun; 48(6):1072-80. PubMed ID: 18373503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of platelet activation and cytokine release during storage of platelet concentrates processed from buffy coats either manually or by the automated OrbiSac system.
    Vetlesen A; Mirlashari MR; Ezligini F; Kjeldsen-Kragh J
    Transfusion; 2007 Jan; 47(1):126-32. PubMed ID: 17207241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Storage of platelet concentrates from pooled buffy coats made of fresh and overnight-stored whole blood processed on the novel Atreus 2C+ system: in vitro study.
    Sandgren P; Callaert M; Shanwell A; Gulliksson H
    Transfusion; 2008 Apr; 48(4):688-96. PubMed ID: 18194379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet capacity of various platelet pooling systems for buffy coat-derived platelet concentrates.
    Dijkstra-Tiekstra MJ; Kuipers W; Setroikromo AC; de Wildt-Eggen J
    Transfusion; 2008 Oct; 48(10):2114-21. PubMed ID: 18647365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Markers of platelet activation and apoptosis during storage of apheresis- and buffy coat-derived platelet concentrates for 7 days.
    Albanyan AM; Harrison P; Murphy MF
    Transfusion; 2009 Jan; 49(1):108-17. PubMed ID: 18954396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The quality of platelet concentrates produced by COBE Spectra and Trima Accel cell separators during storage for 7 days as assessed by in vitro methods.
    Tynngård N; Lindahl TL; Trinks M; Studer M; Berlin G
    Transfusion; 2008 Apr; 48(4):715-22. PubMed ID: 18208416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of buffy coat platelet component production: comparison to platelet-rich plasma platelet production.
    Levin E; Culibrk B; Gyöngyössy-Issa MI; Weiss S; Scammell K; LeFresne W; Jenkins C; Devine DV
    Transfusion; 2008 Nov; 48(11):2331-7. PubMed ID: 18631169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the in vitro properties of apheresis platelets during 7-day storage after interrupting agitation for one or three periods.
    Wagner SJ; Vassallo R; Skripchenko A; Einarson M; Seetharaman S; Moroff G
    Transfusion; 2008 Dec; 48(12):2492-500. PubMed ID: 18764829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Storage of buffy-coat-derived platelets in additive solutions at 4 degrees C and 22 degrees C: flow cytometry analysis of platelet glycoprotein expression.
    Sandgren P; Hansson M; Gulliksson H; Shanwell A
    Vox Sang; 2007 Jul; 93(1):27-36. PubMed ID: 17547562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage.
    Apelseth TØ; Bruserud Ø; Wentzel-Larsen T; Bakken AM; Bjørsvik S; Hervig T
    Transfusion; 2007 Apr; 47(4):653-65. PubMed ID: 17381624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of in vitro storage properties of prestorage pooled whole blood-derived platelets suspended in 100 percent plasma and treated with amotosalen and long-wavelength ultraviolet light.
    Wagner SJ; Skripchenko A; Myrup A; Awatefe H; Thompson-Montgomery D; Moroff G; Carmichael P; Lin L
    Transfusion; 2009 Apr; 49(4):704-10. PubMed ID: 19171001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overnight or fresh buffy coat-derived platelet concentrates prepared with various platelet pooling systems.
    Dijkstra-Tiekstra MJ; Kuipers W; Setroikromo AC; de Wildt-Eggen J
    Transfusion; 2008 Apr; 48(4):723-30. PubMed ID: 18208415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Buffy-coat platelet variables and metabolism during storage in additive solutions or plasma.
    Zhang JG; Carter CJ; Culibrk B; Devine DV; Levin E; Scammell K; Weiss S; Gyongyossy-Issa MI
    Transfusion; 2008 May; 48(5):847-56. PubMed ID: 18298601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Removal by adsorbent beads of biological response modifiers released from platelets, accumulated during storage, and potentially associated with platelet transfusion reactions.
    Tanaka S; Hayashi T; Tani Y; Hirayama F
    Transfusion; 2010 May; 50(5):1096-105. PubMed ID: 20051054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Release of potential immunomodulatory factors during platelet storage.
    Cognasse F; Boussoulade F; Chavarin P; Acquart S; Fabrigli P; Lamy B; Garraud O
    Transfusion; 2006 Jul; 46(7):1184-9. PubMed ID: 16836566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet function under high-shear conditions from platelet concentrates.
    Jilma-Stohlawetz P; Horvath M; Eichelberger B; Koren D; Jilma B; Panzer S
    Transfusion; 2008 Jan; 48(1):129-35. PubMed ID: 17894788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the automated collection and extended storage of apheresis platelets in additive solution.
    Johnson L; Winter KM; Hartkopf-Theis T; Reid S; Kwok M; Marks DC
    Transfusion; 2012 Mar; 52(3):503-9. PubMed ID: 21880041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet activation and residual activation potential during storage of hyperconcentrated platelet products in two different platelet additive solutions.
    Vetlesen A; Mirlashari MR; Torsheim IA; Kjeldsen-Kragh J
    Transfusion; 2005 Aug; 45(8):1349-55. PubMed ID: 16078925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products.
    Li J; de Korte D; Woolum MD; Ruane PH; Keil SD; Lockerbie O; McLean R; Goodrich RP
    Vox Sang; 2004 Aug; 87(2):82-90. PubMed ID: 15355498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.